The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Some of these inhibitors directly target the NLRP3 protein whereas some are aimed at other ... NLRP3 can be activated in response to extracellular ATP and K + efflux through the ATP-gated P2X7 channel ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

micro-RNA-mediated inhibition of p27 translation emerges as a novel mechanism that can reduce p27 in some human cancers. p27 proteolysis is initiated by several different mechanisms. Tyrosine (Tyr ...

In medical practice, IBD is mainly treated with antibodies or antagonists that inhibit NLRP3 activation, including IL-1β receptor blocker Rilonacept, IL-18 blocker GSK1070806, NLRP3-related ATPase ...

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Correction to: Fischer et al., Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People’s Republic of China ...